ArticleBMC neuroscience2025
Characterisation of the expression of P2X7 receptor, cancer stem cell markers and immunological mediators in human high-grade gliomas.
Article in BMC neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the dielectric heterogeneity response of cell lines under electroporation: a microfluidic single-cell on-chip system.Microsystems & nanoengineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionGlioblastoma is the most aggressive primary brain cancer. It is considered an 'immunologically cold' tumour where immune infiltrates are polarised to drive immunosuppression-and therefore tumour proliferation. An important driver of neuroinflammation in glioma is the purinergic P2X7 receptor (P2X7R). While much of the complex glioma microenvironment has been characterised, studies expounding the associations between various cytokines/chemokines, immune cell markers, P2X7R expression and glioma stemness are lacking. Here we aimed to characterise the mRNA expression profiles of various tumour markers, and common 'pro-' and 'anti-tumour' inflammatory mediators, and correlate this to P2X7R expression in human high-grade glioma samples compared to 'healthy' non-tumour post-mortem brain.
methodsHigh grade gliomas were collected from 34 patients undergoing routine tumour resection surgery and compared to 12 'healthy' post-mortem controls. High throughput qPCR was performed on extracted RNA converted to cDNA to examine a custom-made panel of 38 tumour and immune related genes.
resultsMarkers of innate immunity including CD68, S100A9, HLADR, NLPR3, interleukin (IL) 1β, IL-6, TNFα and NF-κB were significantly increased in human derived glioblastoma samples compared to healthy control brain. P2X7R was also upregulated in the glioma microenvironment and its expression was linked to the expression of VEGFB, MMP9, PCNA, IL-4 and IL-8. The level of expression of P2X7R was not associated with overall survival in high grade gliomas. DISCUSSION: Collectively, this study confirms the significant overexpression of P2X7R in human high-grade gliomas as well as highlights the presence of a multidirectional neuroinflammatory milieu in which both tumour-promoting and tumour-suppressive genes are overexpressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.